Coronavirus Update - 07th August 2020

We would like to take this opportunity to thank our clients and staff for their continued support over this period of restricted movement. 

We remain open for business as usual and have started welcoming limited numbers of visitors to site

We fully comply with all government guidance on minimising the risks of COVID-19 and have published our risk assessment here

Our work and case studies

Challenge: A strategy of rapid clinical progression – dose determination to manufacture and to patient administration within 4 days, necessitating a timeline of dose determination to shipping of product to the remote clinical site within 48 hours - repeated for escalating clinical dose levels.


Japanese Big-Pharma Corporation.


Standard manufacturing procedures replaced with project specific procedures, managed through change control, enabling timelines for dose determination/manufacturing order approval to shipment to the clinic to be reduced from 2 -3 weeks to 48 hours. 


Accelerated Manufacturing 48 HRS slide

Accelerated Manufacturing 21 Days slide